Comparative study on the ALA photodynamic effects of human glioma and meningioma cells

Abstract

Background and Objective The purpose of this study was to compare the differential susceptibility to photodynamic therapy (PDT) mediated damage in human U‐105MG glioma cells and CH‐157MN meningioma cells in vitro using 5‐aminolevulinic acid (ALA) as photosensitizer, and to determine if growth factors would enhance PDT‐mediated damage of these cells. Study Design/Materials and Methods U‐105MG or CH‐157MN cells were irradiated with polychromatic light in the presence of ALA. A Xenon lamp (150 W) was used as the light source. For the study on the effect of growth factor on ALA‐PDT, cells were cultured in serum free medium for 24 hours. Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), or platelet derived growth factor BB (PDGF‐BB) was added to achieve a final concentration of 50 ng/ml. 30 minutes later, cells were incubated with ALA (100 μg/ml) for 24 hours, washed, and irradiated with light (11 J/cm2). MTT tetrazolium assays were performed 24 hours after light irradiation. Results The inhibition of metabolic cellular function in U‐105MG cells by ALA depended on both light energy density and ALA concentration. The susceptibility to ALA‐PDT was profoundly lower for CH‐157MN meningioma cells than U‐105MG glioma cells. When incubated with ALA (100 μg/ml), U‐105MG cells exhibited an LD50 around 8 J/cm2 of light irradiation, whereas that of CH‐157MN cells was more than 25 J/cm2. EGF, bFGF, or PDGF‐BB did not have any effects on the susceptibility of these two cell lines to ALA‐PDT. Conclusion ALA‐PDT was more effective in killing U‐105MG glioma cells than CH‐157MN meningioma cells. The differential susceptibility was likely due to differential accumulation of PpIX in these cells. EGF, bFGF, or PDGF‐BB did not have stimulatory or inhibitory effect on the efficiency of ALA‐PDT. Lasers Surg. Med. 24:296–305, 1999. © 1999 Wiley‐Liss, Inc.

Aminolevulinic Acid-Mediated Photodynamic Therapy of Human Meningioma: An in Vitro Study on Primary Cell Lines

“…PDT technically offers a possibility of selective destruction of infiltrating tumor tissue, thereby potentially reducing the rate of recurrence. The first investigations of PDT of meningiomas were carried out in the 1990s [24,35]. Marks et al found dose-dependent toxicity of PDT in five meningioma cell lines and no toxicity in control cell lines.…”

“…A subsequent study of 5-ALA-PDT of immortalized glioma and meningioma cell lines found increased fluorescence and PDT sensitivity of glioma cell lines compared to meningioma cell lines [24]. Although 5-ALA fluorescence guided resection, and PDT is much more established for gliomas than for meningiomas, the potential benefit may be comparable [36,37,38].…”

“…These porphyrins are also phototoxic and have been explored for photodynamic therapy (PDT) of these tumors [18,21,22,23,24,25,26,27,28]. PDT involves the excitation of an administered photosensitizer by light of a specific wavelength to induce energy transfer-producing reactive oxygen species, which then damage the DNA, thereby inducing apoptosis or, at higher doses, necrosis [29].…”

“…While PPIX-PDT appears to be effective in gliomas, the effectivity of 5-ALA-PDT for meningiomas has yet to be established. A previous study comparing ALA-PDT effects between one glioma and one meningioma cell line found a much lower effectiveness in the meningioma cell line [24]. In a more recent study of 5-ALA-PDT in two human meningioma cell lines, the authors found different 5-ALA induced PDT susceptibilities of the cell lines, corresponding to different ferrochelatase activities [33].…”

Quantitative and qualitative 5-aminolevulinic acid–induced protoporphyrin IX fluorescence in skull base meningiomas

“…7,12,17,24 Further, the recent development of quantitative probes 14,26 that can detect and quantify fluorescence invisible to the naked eye is opening new frontiers for the application of this technique in lower-grade tumors, metastases, and meningiomas. In the current study, we present our experience using both state-of-the art qualitative visible fluorescence imaging and a novel quantitative (detected with a spectroscopic probe) fluorescence detection technology for the resection of a skull base meningioma.…”